1st systemic treatment line | 2nd systemic treatment line | 3rd systemic treatment line | 4th systemic treatment line | |
---|---|---|---|---|
N = 107 | N = 59 | N = 34d | N = 18 | |
Clinical triala | ||||
Yes | 36 (33.6%) | 16 (27.1%) | 9 (27.3%) | 0 (0.0%) |
No | 71 (66.4%) | 43 (72.9%) | 24 (72.7%) | 18 (100.0%) |
Treatment classa | ||||
Cytotoxic agent | 65 (91.6%)b | 37 (86.0%)b | 22 (91.7%)b | 12 (66.6%)b |
Hormonal therapy | 2 (2.8%) | 1 (2.3%) | 0 (0.0%) | 0 (2.4%) |
Targeted therapy | 4 (5.6%) | 5 (11.7%) | 2 (8.3%) | 6 (33.4%) |
Treatment combinationsa | ||||
Monotherapy | 38 (53.5%) | 30 (69.8%) | 9 (37.5%) | 17 (94.4%) |
Combination | 33 (46.5%) | 13 (30.2%) | 15 (62.5%) | 1 (0.6%) |
Individual agenta,c | ||||
Doxorubicin | 46 (64.7%) | 10 (23.3%) | 1 (4.2%) | 0 (0.0%) |
Ifosfamide | 17 (23.9%) | 6 (14.0%) | 3 (12.5%) | 1 (5.5%) |
Dacarbazine | 8 (11.3%) | 1 (2.3%) | 1 (4.2%) | 0 (0.0%) |
Gemcitabine | 11 (15.5%) | 11 (25.6%) | 12 (50.0%) | 2 (11.1%) |
Docetaxel | 11 (15.5%) | 10 (23.3%) | 10 (41.7%) | 0 (0.0%) |
Trabectedin | 2 (2.8%) | 9 (20.9%) | 4 (16.4%) | 7 (38.9%) |
At least one off-label agent | ||||
Yes | 27 (38.0%) | 20 (46.5%) | 20 (83.3%) | 11 (61.1%) |
No | 44 (62.0%) | 23 (53.5%) | 4 (16.3%) | 7 (38.9%) |